Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. [electronic resource]
Producer: 20171023Description: 391-401 p. digitalISSN:- 1753-4666
- Aged
- Benzoxazines -- administration & dosage
- Bronchodilator Agents -- administration & dosage
- Cost-Benefit Analysis
- Drug Combinations
- Female
- Forced Expiratory Volume
- Humans
- Italy
- Male
- Markov Chains
- Middle Aged
- Models, Economic
- Pulmonary Disease, Chronic Obstructive -- drug therapy
- Quality-Adjusted Life Years
- Respiratory Function Tests
- Tiotropium Bromide -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.